RCSB PDB - 3APF: Crystal structure of human PI3K-gamma in complex with CH5039699 (original) (raw)
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
[Ohwada, J.](/search?q=citation.rcsb%5Fauthors:Ohwada, J.), [Ebiike, H.](/search?q=citation.rcsb%5Fauthors:Ebiike, H.), [Kawada, H.](/search?q=citation.rcsb%5Fauthors:Kawada, H.), [Tsukazaki, M.](/search?q=citation.rcsb%5Fauthors:Tsukazaki, M.), [Nakamura, M.](/search?q=citation.rcsb%5Fauthors:Nakamura, M.), [Miyazaki, T.](/search?q=citation.rcsb%5Fauthors:Miyazaki, T.), [Morikami, K.](/search?q=citation.rcsb%5Fauthors:Morikami, K.), [Yoshinari, K.](/search?q=citation.rcsb%5Fauthors:Yoshinari, K.), [Yoshida, M.](/search?q=citation.rcsb%5Fauthors:Yoshida, M.), [Kondoh, O.](/search?q=citation.rcsb%5Fauthors:Kondoh, O.), [Kuramoto, S.](/search?q=citation.rcsb%5Fauthors:Kuramoto, S.), [Ogawa, K.](/search?q=citation.rcsb%5Fauthors:Ogawa, K.), [Aoki, Y.](/search?q=citation.rcsb%5Fauthors:Aoki, Y.), [Shimma, N.](/search?q=citation.rcsb%5Fauthors:Shimma, N.)
(2011) Bioorg Med Chem Lett 21: 1767-1772
PubMed: 21316229 Search on PubMed
PubMed Abstract:
Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase and a promising therapeutic target for cancer. Using structure-based drug design (SBDD), we have identified novel PI3K inhibitors with a dihydropyrrolopyrimidine skeleton. Metabolic stability of the first lead series was drastically improved by replacing phenol with aminopyrimidine moiety. CH5132799, a novel class I PI3K inhibitor, exhibited a strong inhibitory activity especially against PI3Kα (IC(50)=0.014 μM). In human tumor cell lines with PI3K pathway activation, CH5132799 showed potent antiproliferative activity. CH5132799 is orally available and showed significant antitumor activity in PI3K pathway-activated human cancer xenograft models in mice.
Organizational Affiliation:
Research Division, Chugai Pharmaceutical Co., Ltd , Kamakura, Kanagawa, Japan. ohwadajn@chugai-pharm.co.jp